<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefaclor: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefaclor: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefaclor: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9211" href="/d/html/9211.html" rel="external">see "Cefaclor: Drug information"</a> and <a class="drug drug_patient" data-topicid="11808" href="/d/html/11808.html" rel="external">see "Cefaclor: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866218"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>CO Cefaclor;</li>
<li>DOM-Cefaclor</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1045856"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (Second Generation)</span></li></ul></div>
<div class="block dop drugH1Div" id="F146923"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> An extended-release tablet dose of 500 mg twice daily is clinically equivalent to an immediate-release capsule dose of 250 mg 3 times daily; an extended-release tablet dose of 500 mg twice daily is <b>NOT</b> clinically equivalent to 500 mg 3 times daily of other cefaclor formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing: </b>Infants, Children, and Adolescents: Immediate release: Oral: 20 to 40 mg/kg/day in divided doses every 8 to 12 hours. Maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1701ac17-544f-4206-a37e-0462fd6cd656">Chronic bronchitis, acute bacterial exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic bronchitis, acute bacterial exacerbation:</b> Adolescents ≥16 years: Extended release: Oral: 500 mg every 12 hours for 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5cc0a30-9c47-4e1b-b93d-a1ebe3cb0cc0">Lower respiratory tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lower respiratory tract infection: Note:</b> Despite FDA approval for lower respiratory tract infection, cefaclor is not included in pediatric guidelines for management of community-acquired pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Immediate release: Oral: 20 to 40 mg/kg/day divided every 8 hours; maximum daily dose: 1,000 mg/<b>day</b>. For outpatient treatment of uncomplicated community-acquired pneumonia in patients who respond to therapy, 5 days of therapy is likely adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33683325','lexi-content-ref-32525203','lexi-content-ref-35040920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33683325','lexi-content-ref-32525203','lexi-content-ref-35040920'])">Ref</a></span>). Longer duration (eg, total course of 7 to 10 days) may be necessary in patients with complicated disease or who do not respond quickly to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-35579504','lexi-content-ref-32525203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-35579504','lexi-content-ref-32525203'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="421fb9d7-bdf8-44c2-b1fd-73ffa0ad118e">Otitis media</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media:</b>
<b>Note:</b> Cefaclor is not a recommended treatment option in the AAP acute otitis media guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Immediate release: Oral: 40 mg/kg/day in divided doses every 8 to 12 hours for 10 days; maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8417429','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8417429','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd705302-04a3-41a9-ae4b-6351f8cd05b4">Skin and soft tissue infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, uncomplicated:</b>
<b>Note:</b> Cefaclor is not currently recommended in IDSA guidelines for treatment of skin and soft tissue infection; alternative agents are preferred (eg, first-generation cephalosporins).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Immediate release: Oral: 20 to 40 mg/kg/day divided every 8 hours; maximum daily dose: 1,000 mg/<b>day</b>. Durations as short as 5 days may be appropriate for uncomplicated infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for nonanaphylactic penicillin allergy):</b>
<b>Note:</b> Narrow-spectrum cephalosporins (eg, cephalexin) are preferred over broader-spectrum cephalosporins such as cefaclor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Immediate release: Oral: 20 mg/kg/day in divided doses every 8 to 12 hours for 10 days; maximum daily dose: 1,000 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b> Infants, Children, and Adolescents: Immediate release: Oral: 20 to 40 mg/kg/day in divided doses every 8 hours; maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1576626','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1576626','lexi-content-ref-Manu.1'])">Ref</a></span>). Duration of therapy should be individualized based on patient age, severity/extent of infection, and clinical response; uncomplicated cystitis may be treated for 3 to 5 days and pyelonephritis for 6 to 10 days; patients &lt;2 years of age may require a longer course (ie, 7 to 14 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-32364593','lexi-content-ref-34860955','lexi-content-ref-25477258','lexi-content-ref-33589366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-32364593','lexi-content-ref-34860955','lexi-content-ref-25477258','lexi-content-ref-33589366'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083947"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">GFR ≥10 mL/minute/1.73 m<sup>2</sup>: Oral: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Oral: Administer 50% of the recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release: </i>Adolescents ≥16 years: Oral: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Hemodialysis shortens half-life by 25% to 30% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release: </i>Infants, Children, and Adolescents: Oral: Administer 50% of the recommended dose; administer after hemodialysis on dialysis days. If not administered after dialysis, administer a supplemental dose following dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release: </i>Adolescents ≥16 years: Oral: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release: </i>Infants, Children, and Adolescents: Oral: Administer 50% of the recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release: </i>Adolescents ≥16 years: Oral: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51083948"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F146904"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9211" href="/d/html/9211.html" rel="external">see "Cefaclor: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> An ER tablet dose of 500 mg twice daily is clinically equivalent to an IR capsule dose of 250 mg 3 times daily; an ER tablet dose of 500 mg twice daily is <b>NOT</b> clinically equivalent to 500 mg 3 times daily of other cefaclor formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: 250 to 500 mg every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: 500 mg every 12 hours.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1701ac17-544f-4206-a37e-0462fd6cd656">Chronic bronchitis, acute bacterial exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic bronchitis, acute bacterial exacerbation: Oral:</b> Extended release: 500 mg every 12 hours for 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae7a1cf7-80fc-4d1d-9ece-3f02289932d6">Pneumonia, community-acquired, outpatient empiric therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired, outpatient empiric therapy (patients with comorbidities): Oral:</b> Immediate release: 500 mg every 8 hours as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-Manu.1'])">Ref</a></span>). Duration is for a minimum of 5 days; patients should be clinically stable with normal vital signs before discontinuing therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47f1db45-3ef1-4229-9b6c-df5d9de732de">Streptococcal pharyngitis, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A (alternative agent for mild, nonanaphylactic penicillin allergy): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin. To avoid the development of resistance, narrower spectrum cephalosporins (eg, cephalexin or cefadroxil) are preferred when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-Pichichero.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-Pichichero.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 250 mg every 8 hours for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use only when first-line agents cannot be used; limited evidence suggests inferior efficacy of oral beta-lactams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection), treatment:</i>
<b>Oral:</b> Immediate release: 250 mg every 8 hours for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654','lexi-content-ref-1576626','lexi-content-ref-10945508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654','lexi-content-ref-1576626','lexi-content-ref-10945508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, prophylaxis for recurrent infection (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be considered in nonpregnant women with bothersome, frequently recurrent cystitis despite nonantimicrobial preventive measures. The optimal duration has not been established; duration ranges from 3 to 12 months, with periodic reassessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-Hooton.2021a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-Hooton.2021a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous prophylaxis: <b>Oral:</b> Immediate release: 250 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7622272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7622272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated (including pyelonephritis):</i>
<b>Oral:</b> Immediate release: 500 mg 3 times daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1621752','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1621752','lexi-content-ref-21292654'])">Ref</a></span>). <b>Note:</b> Oral beta-lactam therapy should generally follow appropriate parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021b','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021b','lexi-content-ref-21292654'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990421"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Manufacturer’s labeling:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe impairment: No dosage adjustment necessary; use with caution in patients with anuria (half-life is prolonged).</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling; hemodialysis shortens half-life by 25% to 30%.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alternative recommendations (off-label dosing) (Aronoff 2007):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral, immediate-release:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Supplement with 250 to 500 mg after dialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Administer 250 to 500 mg every 8 hours.</p></div>
<div class="block doha drugH1Div" id="F50987588"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F146867"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), diarrhea (3% to 4%), nausea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genital pruritus (≤2%), vaginitis (≤2%), vulvovaginal candidiasis (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (3%; including increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased aspartate aminotransferase)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reactions (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (including peripheral edema) (Romano 2008), heart failure, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, maculopapular rash (Romano 2008), skin rash, urticaria (Romano 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin, decreased serum calcium, decreased serum sodium, increased gamma-glutamyl transferase, increased serum phosphate, increased serum potassium, increased serum sodium, menstrual disease</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, dyspepsia, flatulence, gastritis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal urine test finding, dysmenorrhea, dysuria, leukorrhea, nocturia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin, decreased red blood cells, increased MCV, lymphocytopenia, positive direct Coombs’ test, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, dizziness, drowsiness, insomnia, malaise, nervousness, pain, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase in blood specimen, myalgia, neck pain</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, interstitial nephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, syncope, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Kwah 2005), erythema of skin (Romano 2008), Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Romano 2008), anaphylaxis (Grouhi 1999), angioedema (Romano 2008), facial edema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, confusion, hallucination, hypertonia, hyperactive behavior, paresthesia, vertigo</p></div>
<div class="block coi drugH1Div" id="F146882"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to cefaclor, other cephalosporins, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F146864"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylactic reactions have occurred. If a serious hypersensitivity reaction occurs, discontinue and institute emergency supportive measures, including airway management and treatment (eg, epinephrine, antihistamines, and/or corticosteroids).</p>
<p style="text-indent:-2em;margin-left:4em;">• Penicillin allergy: Use with caution in patients with a history of penicillin allergy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• <i>H. influenzae</i> infections: Beta-lactamase-negative, ampicillin-resistant (BLNAR) strains of <i>H. influenzae</i> should be considered resistant to cefaclor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extended-release tablet: An extended-release tablet dose of 500 mg twice daily is clinically equivalent to an immediate-release capsule dose of 250 mg 3 times daily; an extended-release tablet dose of 500 mg twice daily is <b>NOT</b> clinically equivalent to 500 mg 3 times daily of other cefaclor formulations.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878369"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Cefaclor may cause serum sickness-like reaction, which has been reported more frequently in pediatric patients, particularly in patients &lt;5 years of age. The exact incidence of serum sickness-like reaction after a course of cefaclor is uncertain but is likely between 0.024% and 0.5%. Reactions typically involve urticarial rash (often pruritic and migratory) and joint swelling, arthritis, or arthralgia (commonly in hands, feet, or knees), with or without fever, and most often occur with a second or third exposure; severity ranges from mild to severe. Signs and symptoms typically appear around 1 week after cefaclor initiation, but may appear as early as 2 days and as late as 21 days later, and resolve within a few days of discontinuation; joint symptoms may take longer to resolve. Repeat use is not recommended in patients who have previously experienced a serum sickness-like reaction while receiving cefaclor (Hebert 1991; Heckbert 1990; Isaacs 2001; Levine 1985; Martin 1995; Parshuram 1999; Vial 1992; manufacturer's labeling).</p></div>
<div class="block foc drugH1Div" id="F146876"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (150 mL [DSC]); 250 mg/5 mL (150 mL); 375 mg/5 mL (100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block geq drugH1Div" id="F146860"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F146884"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cefaclor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $2.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $5.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Cefaclor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $4.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Cefaclor ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $23.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866219"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block admp drugH1Div" id="F52612374"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules and oral suspension: Administer without regard to meals; shake oral suspension well before using.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release tablets: Do not chew, crush, or split; administer with or within 1 hour of food.</p></div>
<div class="block adm drugH1Div" id="F146879"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsules and oral suspension: Administer without regard to meals; shake oral suspension well before using</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablets: Do not chew, crush, or split; administer with or within 1 hour of food.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation. Capsule may be opened and contents sprinkled onto soft food of choice. Patient should be instructed to swallow the mixture without biting down or chewing.</p></div>
<div class="block sts drugH1Div" id="F146895"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).  Refrigerate suspension after reconstitution and discard after 14 days.</p></div>
<div class="block usep drugH1Div" id="F53565890"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release (capsule and suspension): Treatment of otitis media, lower respiratory tract infections, pharyngitis/tonsillitis, urinary tract infections, and skin and soft tissue infections (FDA approved in ages ≥1 month and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release tablet: Treatment of acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and soft tissue infections (FDA approved in ages ≥16 years and adults).</p></div>
<div class="block mst drugH1Div" id="F146951"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cefaclor may be confused with cephalexin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298983"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F146869"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F146896"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">The bioavailability of cefaclor extended-release tablets is decreased 23% and the maximum concentration is decreased 67% when taken on an empty stomach. Management: Administer with food.</p></div>
<div class="block dic drugH1Div" id="F146886"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Extended release tablets should be taken with or within 1 hour of food.</p></div>
<div class="block pri drugH1Div" id="F5953385"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">An increased risk of teratogenic effects has not been observed following maternal use of cefaclor.</p></div>
<div class="block mopp drugH1Div" id="F53565892"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">With prolonged therapy, monitor CBC and liver function. Observe for signs and symptoms of serum sickness-like reaction (eg, rash, joint swelling or pain, fever) or other hypersensitivity (including anaphylaxis); number and type of stools/day for diarrhea.</p></div>
<div class="block pha drugH1Div" id="F146863"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F146881"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed; acid stable.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes into tissues and fluids including bone, pleural and synovial fluid.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 25% (Aronoff 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months and Children ≤5 years: Mean range: 36 to 60 minutes (McCracken 1978).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.6 to 0.9 hours; prolonged with renal impairment (2.3 to 2.8 hours in anuria).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Capsules, oral suspension: 30 to 60 minutes; Extended-release tablets: 2.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60% to 85% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F58078560"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-infective considerations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC): Goal: ≥40% to 50% (<i>f</i>T) &gt; MIC (bacteriostatic), 60% to 70% (<i>f</i>T) &gt; MIC (bactericidal) (Cazzola 2000; Craig 1996; Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in patients with normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥4 months and Children ≤5 years: C<sub>max</sub> (peak): Steady state, immediate release: 10 mg/kg/dose every 6 hours: 6.7 mg/L (fed), 10.8 mg/L (fasting) (McCracken 1978).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults, C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:10em;">Single dose, delayed release: 750 mg: ~8.6 mg/L (Cazzola 2000; Tomić 2016).</p>
<p style="text-indent:-2em;margin-left:10em;">Steady state, immediate release: 500 mg every 8 hours: 15.2 ± 4.75 mg/mL (Barbhaiya 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i> Generally &lt;1 hour; varies based on organism (Craig 1991; Craig 1998; Dubois 2000).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F146887"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ceclocare | Ceclor | Cloracef | Cloracef mr | Recocef | Tabiclor | Vercef</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cec | Cefaclor fabra | Cefaclor richet | Cefloboxal | Distaclor | Kwicap</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cec | Ceclor | Ceclor duo | Cefastad</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aclor | Apo-cefaclor | Apo-cefaclor cd | Ceclor | Cefaclor cd | Cefaclor sandoz | Cefaclor-bc | Cefaclor-GA | Cefkor | Cefkor cd | Cm cefaclor | Dbl cefaclor | Karlor | Karlor cd | Keflor | Ozcef | Tw cefaclor</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Abaclor | Alclor | Biocef | Ceclor | Cefclor | Ceflon | Cfl | Clocef | Clorocef | Loracef | Navacef | Oticef | Oticlor | Sefalor</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Doccefaclo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cec | Ceclor | Medoclor | Razicef</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Ceclor af | Ceclor bd | Cefaclor monoidratado | Cefacloren | Clorcin-ped | Faclor | Novacef | Plecor | Reflax</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ceclor</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Alfatil | Bacticef | Oralcef</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Keflor</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bi li | Ceclor | Cefaclor stada | Ji da you ka | Jinshi ke zhi | Ke fu le | Ke luo | Keflor | Lai fu luo | Man ning | Ou jia | Sheng han | Shi hua luo | Shuai xian | Su ke le | Xi fu lai | Xi you luo | Xin da luo | Xin ke nuo | Xincatlor | You ke luo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Distaclor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alfacet | Cec | Ceclor | Cefaclor al | Serviclor | Vercef</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cec | Ceclorbeta | Cef diolan | Cefa wolff | Cefaclor 1a pharma | Cefaclor al | Cefaclor Aristo | Cefaclor beta | Cefaclor CT | Cefaclor ratiopharm | Cefaclor sandoz | Cefaclor stada | Cefaclor wolff | Cephalodoc | Hefaclor | Infectocef | Sigacefal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cec | Ceclor | Cefaclor feltrex | Cefaltrex | Cefamid | Cefcor | Cefcor MR | Cefin | Clorcefor | Clorotir | Falcef | Infaclor | Loclor | Lufraclor | Suclor</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Cefraspor</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ceclor</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bacticlor | Ceclor | Cefaclor | Cloracef | Clorocef | Misaclor | Serviclor</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Cefaclor bexal | Cefaclor normon</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Tabiclor</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cefaklor ranbaxy | Kefolor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alfatil | Alphexine | Cefaclor G Gam | Cefaclor merck | Cefaclor rpg</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bacticlor mr | Cefaclor cox | Cefaclor kent | Cefaclor sandoz | Distaclor | Keftid</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Afecton | Camirox | Ceclor | Cefacloril | Makovan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Castal | Ceclor | Ceclorin | Cefalor | Clortrin | Medoclor | Neo clora | Phaclor | Quali-ceclor | Qualiphor | Soficlor | Syntoclor | Vercef</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Cecloretta | Cefaclor al | Cefaclor ratiopharm | Serviclor | Vercef</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Capabiotic | Ceclor | Ceflex | Cloracef | Especlor | Forifek | Medikoncef | Soclor</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cefager | Distaclor | Keftid | Pinaclor</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Cefalor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Articlor | Clorocef | Distaclor | Duclor | Eclor | Eclor premix | Halclor | Halocef | Keflor | Radiclor | Uniclor | Vercef | Zenclor</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Altaclor | Bacticef | Bactigram | Cefaclor doc | Cefaclor eg | Cefaclor K24 | Cefulton | Citiclor | Clorad | Clorazer | Dorf | Erreclor | Eurocefix | Fuclode | Geniclor | Kliacef | Lafarclor | Macovan | Necloral | Oralcef | Panacef | Performer | Selanir | Selviclor | Takecef | Tibifor | Valeclor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Biocef | Ceclor | Cefabac | Cloracef | Forbatec | Midocef | Pharmaclor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alenfral | Alenfral choseido | Ccl | Ceclodan | Cefaclor maruko | Ericanal | Hishiyachlor | Kefpolin | Kefral | Kulilel amel | Kulilel mita | Kulilel tatumi | Ruberal isei | Ruberal tobishi | Saltskural | Saltskural kayaku | Saltskural shiono | Tofarol | Tokiclor</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cefclor | Clofort | Halocef | Labclor | Medacef | Vercef</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ahngook cefaclor | Aju cefaclor | Alvogen cefaclor hydrate | Anticle | Anticlor | Antilor | Aprogen cefaclor | Arlico cefaclor | Auclor | Biclor | Biclor sr | Binex cefaclor | Bm cefaclor | Cecid | Cecl | Cecla | Ceclem | Ceclen | Ceclex | Ceclin | Ceclor | Ceclor mr | Cecra | Cecradin sr | Cecrocin | Cecrun | Cectin | Cefa | Cefa s | Cefacid | Cefacide | Cefacl | Cefacla | Cefacle | Cefaclean | Cefacli | Cefaclin | Cefaclin er | Cefaclor | Cefaclor Asia | Cefaclor cap. boryung | Cefaclor capsule 250 mg rp | Cefaclor Chunggei | Cefaclor dry syrup sk | Cefaclor guju | Cefaclor ss | Cefaclridid | Cefacool | Cefacro | Cefaculor | Cefacure | Cefalasin | Cefalex | Cefalex sr | Cefalon | Cefalor | Cefapos | Cefarasin | Cefaro | Cefarox | Cefazine | Ceficle | Cefler | Cefnil | Ceforin | Cefotamin | Cefotamin sr | Cefre | Celfaclor | Celor | Cenaf | Cencla | Cepclor | Ceracl | Cerecle | Cereo | Cerocle | Cesid | Cevacl | Citclor | Cleancef | Clex | Clif | Clocef | Clorwin | Cmg cefaclor | Cofacle | Cyclor | Dae hwa cefaclor | Daewoo cefaclor | Dongkoo cefaclor hydrate | Dongkoo cefaclor sr | Dongwha cefaclor | Eden cefaclor | Elclor | Esclor | Facle | Faclerin | Faclor | Facro | Fronclor | Glo cefaclor sr | Hanaclor | Hucefa | Huclor | Huniz cefaclor | Hyundai cefaclor | Icefa | Il yang cefaclor | Ildong cefaclor | Ilhwa cefaclor | Ilyangbio cefaclor | Itclor | Jeclor | Joonclor | Jr cefaclor | Jw cefaclor | Kdc cefaclor | Kemocin | Kepla | Kms cefaclor | Korus cefaclor | Kwangdong cefaclor | Kyongbo cefaclor | Litecefa | Medica cefaclor | Medica cefaclor sr | Micla | Miclor | Myungin cefaclor | Myungmoon cefaclor | Nelson cefaclor | Neocef | Newcefa | Newclor | Newfaclor | Newgen cefaclor retard | Newgenclor | Newporin | Newporine | Nuclor | Nuclur | Olcefa | Oraclor | Panacef | Pharma cefaclor sr | Pharmaking cefaclor | Pharmgen cefaclor | Pharvis cefaclor | Sake | Samnam cefaclor | Samsung cefaclor | Sebacle | Secl | Seclor | Seporin | Sera | Sinil cefaclor | Spc cefaclor | Syntex cefaclor | Taiguk cefaclor | Uniclor | Withus cefaclor | Wonclor | Wooridul cefaclor | Youngil cefaclor | Youngpoong cefaclor | Yuhan cefaclor | Yuhan cefaclor sr | Yungjin cefaclor | Yuyu cefaclor | Zecra</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ceclocare | Ceclor | Ceclor mr | Cefabac | Cloracef | Cloracef mr | Medacef | Recocef | Tabiclor | Vercef</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Cloracef | Cloracef mr | Zeflox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cec | Ceclor | Vercef</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cec | Ceclor | Doccefaclo</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Vercef</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Alfacefal | Alfatil | Cloracef | Clorotir</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Arcefal | Bixelor C | Bixelor c | Cec | Ceclor | Cefaclor Ranbaxy | Cefalan | Cefalan mr | Ceflacid | Fasiclor | Fluban | Inclor | Ranclor | Serviclor | Tecnoclor | Teraclox</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel Cefaclor | Cefalon | Efaclor | Sefaclor | Sifaclor | Soficlor | Vercef</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Cefaclor sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Ceclor cd | Cefaclor sandoz | Clorotir | Keflor | Ranbaxy cefaclor</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ceclomek | Ceclor | Cefabac | Cefatrim | Cefcor | Cefraspor | Clorotir | Gramactam | Infaclor | Oraclor | Panacef</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Brelox | Ceclobid | Ceclor | Cecrocef | Cefaclor Am-Europharma | Cefar | Ceflor | Cefmed | Cfc | Cloran | Clorcef | Clorgen | Clormed | Clorotir | Ephron | Lorcef | Reclor | Remedlor | Rimaclor | Tgp genclor | Vefarol | Vercef | Verzat | Xelent | Xeztron | Zifclor | Zyrcef</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Afalor | Ag-Clor | Cariclor | Cavalor | Ceclor | Ceclor mr | Cefa Z | Cefalor | Cefanol | Cefatek | Cefawan | Cefclor | Cefgard | Ceflis | Cefmoni | Cefolom | Cefticlor | Cekrol | Cephlo | Cetaclor | Cloratec | Clorex | Clorizat | Corvin | Danvar | Deduclol | Deucef | Distaclor | Enspor | Exlor | Geflor | Hiclor | Inclor | Ipraclor | Kilbac | Klorex | Lexiclor | Meclor | Medclor | Misflor | N clor | Nettle | Neutroclor | Niflor | Pechlor | Plorsaf | Plozat | Proclor | Reclor | Ridbac | Ridclor | Ridclor ds | Sac lor | Sayflar | Seclor | Slate | Slate mr | Sn ceflor | Sn faclor | Soclar | Supren | Teklor | Trinkle | Varco | Vesclor | W Clor | X clor | Zuper</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alfacet | Apo-cefaclor | Ceclor | Cek | Kloracef | Panclor | Serviclor | Vercef</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Ceclor cd | Cefaclor | Cefaclor extended release</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ceclor</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Ceclor MR | Cloracef | Cloracef Forte | Medacef | Tabiclor | Tabiclor MR</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ceclodyne mr | Ceclor | Ceclor mr | Ceclozone MR | Cefaclor arena | Cefaclor terapia | Cefaklor | Cloracef</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alfacet | Ceclor | Cefaclor stada | Vercef</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Biocef | Ceclor | Cloracef | Forticef | Medacef | Recocef | Tabiclor</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kefolor</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cleancef | Soficlor | Vercef</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Cefa cl | Taracef</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Serviclor | Vercef</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cecef R | Ceclor | Cefaclor stada | Cefclorstar | Celco | Clorotir | Distaclor | Hofclor | Kressclor | Sifaclor | Ufaclor | Vercef</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Alfatil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ceclor | Cekloteva | Kefsid | Losefar | Sanocef</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alfacol | Cefac | Cefachlor | Cefalo | Cekor | Celor | Cero | Keflor | Keflor af | Keflu | Kerfenmycin | Kerloli | Rolfec | Swiflor | U-clor | Uclor</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Biclor | Ceclor | Vercef</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Hiclor | Recocef</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ceclor</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Dazofort | Imeclor | Kefcin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-cefaclor | Cec | Ceclor | Cloracef | Lilly-cefaclor | Rolab-cefaclor | Vercef</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Lilly-cefaclor</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Vercef</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31958969">
<a name="31958969"></a>Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of uncomplicated urinary tract infection in pediatric patients. <i>Ann Pharmacother</i>. 2020;54(8):757-766. doi:10.1177/1060028019900650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/31958969/pubmed" id="31958969" target="_blank">31958969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8239186">
<a name="8239186"></a>American Thoracic Society, “Guidelines for the Initial Management of Adults With Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy,” <i>Am Rev Respir Dis</i>, 1993, 148(5):1418-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/8239186/pubmed" id="8239186" target="_blank">8239186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31042112">
<a name="31042112"></a>Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. <i>J Urol</i>. 2019;202(2):282-289. doi:10.1097/JU.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/31042112/pubmed" id="31042112" target="_blank">31042112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 61, 153.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2393281">
<a name="2393281"></a>Barbhaiya RH, Shukla UA, Gleason CR, et al. Phase I study of multiple-dose cefprozil and comparison with cefaclor. <i>Antimicrob Agents Chemother</i>. 1990;34(6):1198-1203. doi:10.1128/AAC.34.6.1198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/2393281/pubmed" id="2393281" target="_blank">2393281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (PIDS/IDSA). <i>Clin Infect Dis.</i> 2011;53(7):e25-76. doi:10.1093/cid/cir531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7622272">
<a name="7622272"></a>Brumfitt W, Hamilton-Miller JM. A comparative trial of low dose cefaclor and macrocrystalline nitrofurantoin in the prevention of recurrent urinary tract infection. <i>Infection</i>. 1995;23(2):98-102. doi:10.1007/BF01833874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/7622272/pubmed" id="7622272" target="_blank">7622272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21742459">
<a name="21742459"></a>Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: a literature review. <i>J Emerg Med.</i> 2012; 42(5):612-620.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/21742459/pubmed" id="21742459" target="_blank">21742459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10877516">
<a name="10877516"></a>Cazzola M, Di Perna F, Boveri B, Di Marco F, Diamare F, Centanni S. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis. <i>J Chemother</i>. 2000;12(3):216-222. doi:10.1179/joc.2000.12.3.216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/10877516/pubmed" id="10877516" target="_blank">10877516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefaclor.1">
<a name="Cefaclor.1"></a>Cefaclor capsules [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefaclor.2">
<a name="Cefaclor.2"></a>Cefaclor extended-release tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefaclor.3">
<a name="Cefaclor.3"></a>Cefaclor for oral suspension, USP [prescribing information]. Claymont, DE: Azorian Pharma LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8852915">
<a name="8852915"></a>Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. <i>Pediatr Infect Dis J.</i> 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/8852915/pubmed" id="8852915" target="_blank">8852915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis</i>. 1998;26(1):1-10;quiz 11-2. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>CMNEEJ. </i>1991;13(16)121-128.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10904192">
<a name="10904192"></a>Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. <i>Diagn Microbiol Infect Dis</i>. 2000;37(3):187-193. doi:10.1016/s0732-8893(00)00141-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/10904192/pubmed" id="10904192" target="_blank">10904192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32364593">
<a name="32364593"></a>Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. <i>JAMA Netw Open</i>. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/32364593/pubmed" id="32364593" target="_blank">32364593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10103342">
<a name="10103342"></a>Grouhi M, Hummel D, Roifman CM. Anaphylactic reaction to oral cefaclor in a child. <i>Pediatrics</i>. 1999;103(4):e50. doi:10.1542/peds.103.4.e50<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/10103342/pubmed" id="10103342" target="_blank">10103342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021a">
<a name="Hooton.2021a"></a>Gupta K. Recurrent simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 11, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi: 10.1093/cid/ciq257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1802903">
<a name="1802903"></a>Hebert AA, Sigman ES, Levy ML. Serum sickness-like reactions from cefaclor in children. <i>J Am Acad Dermatol</i>. 1991;25(5, pt 1):805-808. doi:10.1016/s0190-9622(08)80973-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/1802903/pubmed" id="1802903" target="_blank">1802903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2115293">
<a name="2115293"></a>Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. <i>Am J Epidemiol</i>. 1990;132(2):336-342. doi:10.1093/oxfordjournals.aje.a115663<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/2115293/pubmed" id="2115293" target="_blank">2115293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021b">
<a name="Hooton.2021b"></a>Hooton TM, Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3242837">
<a name="3242837"></a>Hyslop DL. Cefaclor Safety Profile: A Ten Year Review. <i>Clin Ther</i>. 1988;11(suppl A):83-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/3242837/pubmed" id="3242837" target="_blank">3242837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1621752">
<a name="1621752"></a>Hyslop DL, Bischoff W. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis. <i>Am J Med</i>. 1992;92(6A):86S-94S. doi:10.1016/0002-9343(92)90614-h<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/1621752/pubmed" id="1621752" target="_blank">1621752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1576626">
<a name="1576626"></a>Iravani A. Loracarbef versus cefaclor in the treatment of cystitis and asymptomatic bacteriuria. <i>Clin Ther</i>. 1992;14(1):54-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/1576626/pubmed" id="1576626" target="_blank">1576626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11468048">
<a name="11468048"></a>Isaacs D. Serum sickness-like reaction to cefaclor. <i>J Paediatr Child Health</i>. 2001;37(3):298-299. doi:10.1046/j.1440-1754.2001.00632.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/11468048/pubmed" id="11468048" target="_blank">11468048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35579504">
<a name="35579504"></a>Kuitunen I, Jääskeläinen J, Korppi M, Renko M. Antibiotic treatment duration for community acquired pneumonia in outpatient children in high-income countries - a systematic review and meta-analysis. <i>Clin Infect Dis</i>. 2022;ciac374. doi:10.1093/cid/ciac374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/35579504/pubmed" id="35579504" target="_blank">35579504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15968449">
<a name="15968449"></a>Kwah YC, Leow YH. Not all pustules are infective in nature: acute generalised exanthematous pustulosis causing pustular eruptions in an elderly woman. <i>Singapore Med J</i>. 2005;46(7):349-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/15968449/pubmed" id="15968449" target="_blank">15968449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34860955">
<a name="34860955"></a>Lashkar MO, Nahata MC. Antimicrobial pharmacotherapy management of urinary tract infections in pediatric patients. <i>J Pharm Technol</i>. 2018;34(2):62-81. doi:10.1177/8755122518755402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/34860955/pubmed" id="34860955" target="_blank">34860955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10945508">
<a name="10945508"></a>Leigh AP, Nemeth MA, Keyserling CH, Hotary LH, Tack KJ. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. <i>Clin Ther</i>. 2000;22(7):818-825. doi:10.1016/s0149-2918(00)80054-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/10945508/pubmed" id="10945508" target="_blank">10945508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3161007">
<a name="3161007"></a>Levine LR, “Quantitative Comparison of Adverse Reactions to Cefaclor vs Amoxicillin in a Surveillance Study,” <i>Pediatr Infect Dis</i>, 1985, 4(4):358-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/3161007/pubmed" id="3161007" target="_blank">3161007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069359">
<a name="10069359"></a>Marshall WF and Blair JE, “The Cephalosporins,” <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/10069359/pubmed" id="10069359" target="_blank">10069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7739819">
<a name="7739819"></a>Martin J, Abbott G. Serum sickness like illness and antimicrobials in children. <i>N Z Med J</i>. 1995;108(997):123-124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/7739819/pubmed" id="7739819" target="_blank">7739819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-711649">
<a name="711649"></a>McCracken GH Jr, Ginsburg CM, Clahsen JC, Thomas ML. Pharmacokinetics of cefaclor in infants and children. <i>J Antimicrob Chemother</i>. 1978;4(6):515-521. doi:10.1093/jac/4.6.515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/711649/pubmed" id="711649" target="_blank">711649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Respir Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10365368">
<a name="10365368"></a>Parshuram CS, Phillips RJ, Nash MC. Serum sickness in a paediatric emergency department: the role of cefaclor. <i>J Paediatr Child Health</i>. 1999;35(2):223-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/10365368/pubmed" id="10365368" target="_blank">10365368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33683325">
<a name="33683325"></a>Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER Randomized Clinical Trial. <i>JAMA Pediatr</i>. 2021;175(5):475-482. doi:10.1001/jamapediatrics.2020.6735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/33683325/pubmed" id="33683325" target="_blank">33683325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pichichero.2022">
<a name="Pichichero.2022"></a>Pichichero ME. Treatment and prevention of streptococcal pharyngitis in adults and children. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8417429">
<a name="8417429"></a>Rodriguez WJ, Khan W, Sait T, et al. Cefixime vs. cefaclor in the treatment of acute otitis media in children: a randomized, comparative study. <i>Pediatr Infect Dis J</i>. 1993;12(1):70-74. doi:10.1097/00006454-199301000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/8417429/pubmed" id="8417429" target="_blank">8417429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18762521">
<a name="18762521"></a>Romano A, Gaeta F, Valluzzi RL, Alonzi C, Viola M, Bousquet PJ. Diagnosing hypersensitivity reactions to cephalosporins in children. <i>Pediatrics</i>. 2008;122(3):521-527. doi:10.1542/peds.2007-3178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/18762521/pubmed" id="18762521" target="_blank">18762521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32525203">
<a name="32525203"></a>Same RG, Amoah J, Hsu AJ, et al. The association of antibiotic duration with successful treatment of community-acquired pneumonia in children. <i>J Pediatric Infect Dis Soc</i>. 2021;10(3):267-273. doi:10.1093/jpids/piaa055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/32525203/pubmed" id="32525203" target="_blank">32525203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3300459">
<a name="3300459"></a>Saxon A, Beall GN, Rohr AS, et al, “Immediate Hypersensitivity Reactions to Beta-Lactam Antibiotics,” <i>Ann Intern Med</i>, 1987, 107(2):204-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/3300459/pubmed" id="3300459" target="_blank">3300459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2012;55(10):e86-102. doi:10.1093/cid/cis629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2405586">
<a name="2405586"></a>Smith GH, “Oral Cephalosporins in Perspective,” <i>DICP</i>, 1990, 24(1):45-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/2405586/pubmed" id="2405586" target="_blank">2405586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477258">
<a name="25477258"></a>Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. <i>Eur Urol</i>. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/25477258/pubmed" id="25477258" target="_blank">25477258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America (IDSA). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25124380">
<a name="25124380"></a>Terico AT, Gallagher JC. Beta-lactams hypersensitivity and cross-reactivity. <i>J Pharm Pract</i>. 2014;27(6):530-544.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/25124380/pubmed" id="25124380" target="_blank">25124380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33589366">
<a name="33589366"></a>'t Hoen LA, Bogaert G, Radmayr C, et al. Update of the EAU/ESPU guidelines on urinary tract infections in children. <i>J Ped Urol</i>. 2021;17(2):200-207. doi:10.1016/j.jpurol.2021.01.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/33589366/pubmed" id="33589366" target="_blank">33589366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26886327">
<a name="26886327"></a>Tomić Z, Tomas A, Vukmirović S, et al. Do we bury antibacterials when launching? Cefaclor example. <i>J Pharm Sci</i>. 2016;105(3):1295-1300. doi:10.1016/j.xphs.2015.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/26886327/pubmed" id="26886327" target="_blank">26886327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis</i>. 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1504397">
<a name="1504397"></a>Vial T, Pont J, Pham E, Rabilloud M, Descotes J. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. <i>Ann Pharmacother</i>. 1992;26(7-8):910-914. doi:10.1177/106002809202600708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/1504397/pubmed" id="1504397" target="_blank">1504397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35040920">
<a name="35040920"></a>Williams DJ, Creech CB, Walter EB, et al. Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial. <i>JAMA Pediatr</i>. 2022;176(3):253-261. doi:10.1001/jamapediatrics.2021.5547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/35040920/pubmed" id="35040920" target="_blank">35040920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10090000">
<a name="10090000"></a>Wright AJ, “The Penicillins,” <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefaclor-pediatric-drug-information/abstract-text/10090000/pubmed" id="10090000" target="_blank">10090000</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13122 Version 275.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
